Drug is a 'key biosimilar value driver' for Sandoz (Il Sole 24 Ore Radiocor) - Zurich, 22 Apr - Sandoz, a Swiss producer of generic and biosimilar medicines, said that the European Commission has granted marketing authorization for the gastroenterology, dermatology and rheumatology drug Pyzchiva.

Pyzchiva, which was developed and registered by Samsung Bioepis "is a key biosimilar value driver" for Sandoz over the mid-term and "this approval is a major step in advancing Sandoz growth strategy," it added.

Sandoz entered into a development and commercialization agreement with Samsung Bioepis in September 2023. Under the terms of the agreement, the Swiss company has the right to commercialize Pyzchiva in the US, Canada, the European Economic Area (EEA), Switzerland and the UK. Samsung Bioepis remains responsible for development, registration, intellectual property, manufacturing and supply.

AAA-Web

(RADIOCOR) 22-04-24 19:23:24 (0675) 5 NNNN